Want to see IN:NEULANDLAB full AI Analyst Report?
NEULANDLAB Stock Chart & Stats
₹18570.85
₹448.00(2.42%)
At close: 4:00 PM EDT
₹18570.85
₹448.00(2.42%)
Day’s Range― - ―
52-Week Range₹11,500.00 - ₹23,899.00
Previous CloseN/A
Volume27.75K
Average Volume (3M)2.41K
Market Cap
₹298.87B
Enterprise Value₹153.58K
Total Cash (Recent Filing)₹766.70M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)59.0
Beta1.27
Next Earnings
Nov 05, 2026EPS Estimate
69.51Next Dividend Ex-DateN/A
Dividend Yield0.15%
Share Statistics
EPS (TTM)387.97
Shares Outstanding12,829,889
10 Day Avg. Volume1,318
30 Day Avg. Volume2,408
Financial Highlights & Ratios
PEG Ratio1.06
Price to Book (P/B)8.23
Price to Sales (P/S)7.63
P/FCF Ratio-262.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)326.8
Revenue Forecast (FY)₹24.32B
Bulls Say, Bears Say
Bulls Say
Strong Revenue And Earnings GrowthStrong revenue and earnings growth indicate expanding demand for Neuland’s API and custom manufacturing services, supporting scale benefits and reinforcing its position with global pharmaceutical customers over the medium term.
Sustained ProfitabilityPersistently healthy net and operating margins demonstrate effective execution and valuable pharmaceutical manufacturing capabilities. This profitability provides internal funding capacity and resilience as the company expands complex API and contract manufacturing operations.
Conservatively Leveraged Balance SheetLow leverage limits interest and refinancing risk while preserving financial flexibility for capacity expansion, process development, and customer projects. Steady equity growth and strong historical returns on equity also support the quality of the balance sheet.
Bears Say
Negative Free Cash FlowNegative free cash flow reduces near-term financial flexibility despite strong reported profits. If driven by sustained investment or working-capital needs, it could increase reliance on internal execution and constrain the pace of future capacity expansion.
Meaningful Margin CompressionThe sharp gross-margin decline signals exposure to input costs and product-mix changes. Unless manufacturing efficiency, pricing, or mix improves, sustained compression could weaken earnings quality and reduce the benefits of otherwise strong revenue growth.
Moderate Profit-to-Cash ConversionOperating cash flow below net income indicates that accounting profits are not converting fully into cash, potentially reflecting working-capital absorption or timing effects. Persistent weak conversion would limit internally generated funding and raise execution risk.
Neuland Laboratories Ltd. News
NEULANDLAB FAQ
What was Neuland Laboratories Ltd.’s price range in the past 12 months?
Neuland Laboratories Ltd. lowest stock price was ₹11500.00 and its highest was ₹23899.00 in the past 12 months.
What is Neuland Laboratories Ltd.’s market cap?
Neuland Laboratories Ltd.’s market cap is ₹298.87B.
When is Neuland Laboratories Ltd.’s upcoming earnings report date?
Neuland Laboratories Ltd.’s upcoming earnings report date is Nov 05, 2026 which is in 72 days.
How were Neuland Laboratories Ltd.’s earnings last quarter?
Neuland Laboratories Ltd. released its earnings results on Aug 05, 2026. The company reported ₹115 earnings per share for the quarter, beating the consensus estimate of ₹60.01 by ₹54.99.
Is Neuland Laboratories Ltd. overvalued?
According to Wall Street analysts Neuland Laboratories Ltd.’s price is currently Overvalued.
Does Neuland Laboratories Ltd. pay dividends?
Neuland Laboratories Ltd. pays a Annually dividend of ₹34 which represents an annual dividend yield of 0.15%. See more information on Neuland Laboratories Ltd. dividends here
What is Neuland Laboratories Ltd.’s EPS estimate?
Neuland Laboratories Ltd.’s EPS estimate is 69.51.
How many shares outstanding does Neuland Laboratories Ltd. have?
Neuland Laboratories Ltd. has 12,829,889 shares outstanding.
What happened to Neuland Laboratories Ltd.’s price movement after its last earnings report?
Neuland Laboratories Ltd. reported an EPS of ₹115 in its last earnings report, beating expectations of ₹60.01. Following the earnings report the stock price went up 3.507%.
Which hedge fund is a major shareholder of Neuland Laboratories Ltd.?
Currently, no hedge funds are holding shares in IN:NEULANDLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Neuland Laboratories Ltd.
Neuland Laboratories Ltd. operates as a global developer and supplier of active pharmaceutical ingredients (APIs), distributing its products across India, Europe, the United States, and other international markets. These APIs are crucial components in treatments spanning a wide array of therapeutic areas, such as respiratory conditions (antiasthmatics), cardiovascular health, fungal infections, seizure control (anticonvulsants), central nervous system disorders, bacterial infections (fluoroquinolones, antibacterial), mental health (antipsychotic), and Parkinson's disease. Additionally, the company provides bespoke manufacturing solutions and specialized peptide synthesis services. Founded in 1984, Neuland Laboratories is headquartered in Hyderabad, India.
Technical Analysis
Aurobindo Pharma Ltd
―
Divi's Laboratories Limited
―
Glenmark Life Sciences Limited
―
Granules India Limited
―
Laurus Labs Ltd.
―